EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Katie Ross iD, Ketan Kulkarni iD, Tamara MacDonald, Teresa Pinto

Pediatric Diabetes · 2023

DOI: 10.1155/2023/1057639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Diabetes, 2023. Verfasst von Katie Ross und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Dalhousie University, Halifax B3H 4R2, Canada. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Diabetes Mellitus, Induction Chemotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medication-induced diabetes (MID) is common during induction therapy for pediatric acute lymphoblastic leukemia (ALL) and has potentially significant negative consequences. Reported risk factors for MID are variable with limited data comparing patients treated with standard-risk (SR) vs. high-risk (HR) regimens. This study aims to evaluate the incidence and risk factors for MID during induction in patients with ALL from the Maritimes over a 20-year period. We performed a retrospective single-center study of 262 patients (142 males, 120 females) diagnosed with ALL at IWK Health in Halifax, Nova Scotia, Canada, from 2000 to 2019. Older age, higher body mass index, greater central nervous system status, Trisomy 21, and prednisone steroid type were risk factors associated with MID in our cohort. HR patients developed significantly more complications than SR patients including MID and infection. Screening for MID should be routine during ALL induction treatment, particularly in those with HR disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaDiabetes MellitusInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleChildRetrospective StudiesAdolescentChild, PreschoolRisk FactorsIncidenceRisk AssessmentNova ScotiaInfant

Autor:innen und Institutionen

  • Faculty of Medicine, Dalhousie University, Halifax B3H 4R2, Canada.
  • Division of Hematology/Oncology, Department of Pediatrics, IWK Health, Halifax B3K 6R8, Canada.
  • Department of Pharmacy, IWK Health, Halifax B3K 6R8, Canada.
  • Faculty of Health Professions, Dalhousie University, Halifax B3H 4R2, Canada.
  • Division of Endocrinology, Department of Pediatrics, IWK Health, Halifax B3K 6R8, Canada.

ORCID-Profile: Katie Ross, Ketan Kulkarni

Zitieren

APA

Ross, K., Kulkarni, K., MacDonald, T., & Pinto, T. (2023). Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia. Pediatric Diabetes. https://doi.org/10.1155/2023/1057639

Vancouver

Ross K, Kulkarni K, MacDonald T, Pinto T. Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia. Pediatric Diabetes. 2023. doi:10.1155/2023/1057639

BibTeX
@article{Ross2023,
  author = {Ross, Katie and Kulkarni, Ketan and MacDonald, Tamara and Pinto, Teresa},
  title = {Assessing Risk Classification in Medication-Induced Diabetes during Induction Therapy in Pediatric Acute Lymphoblastic Leukemia},
  journal = {Pediatric Diabetes},
  year = {2023},
  doi = {10.1155/2023/1057639}
}
Kostenlos starten →